A Study Of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer.

Official Title

A Phase III, Double-blind, Placebo-controlled, Randomized Study Of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer.

Summary:

This study will evaluate the efficacy and safety of ipatasertib in combination with atezolizumab and paclitaxel in locally advanced or metastatic Triple-Negative Breast Cancer (TNBC) previously untreated in this setting.

Trial Description

Primary Outcome:

  • Investigator-assessed Progression Free Survival (PFS)
  • Overall Survival (OS)
Secondary Outcome:
  • Overall Response Rate (ORR)
  • Duration of Response (DOR)
  • Clinical Benefit Rate (CBR)
  • Mean and mean changes from baseline score in participant-reported function (role, physical)
  • Mean and mean changes from baseline score in function in participant-reported Global Health Status (GHS)/Quality of Life (QoL) by assessment timepoint and between treatment arms
  • Progression Free Survival (PFS) for participants with Programmed Death-Ligand 1 (PD-L1)-non-positive tumours
  • Overall Survival (OS) for participants with PD-L1-non-positive tumours
  • Overall Response Rate (ORR) for participants with PD-L1-non-positive tumours
  • Progression Free Survival (PFS) for participants with PIK3CA/AKT1/PTEN-altered tumours
  • Overall Survival (OS) for participants with PIK3CA/AKT1/PTEN-altered tumours
  • Overall Response Rate (ORR) for participants with PIK3CA/AKT1/PTEN-altered tumours
  • Duration of Response (DOR) for participants with PIK3CA/AKT1/PTEN-altered tumours
  • Number of Participants with Adverse Events (AEs)
  • Plasma concentration of ipatasertib and its metabolite (G037720) (ng/mL) at specified timepoints
  • Serum concentration of atezolizumab (µg/mL) at specified timepoints
  • Level of Anti-Drug Antibodies (ADAs) (%) to Atezolizumab
This study will evaluate the efficacy, safety and pharmacokinetics of ipatasertib in combination with atezolizumab and paclitaxel in locally advanced unresectable or metastatic triple-negative breast cancer (TNBC) previously untreated in this setting. Participants with Programmed Death-Ligand 1 (PD-L1) non-positive and PD-L1 positive tumours will be independently enrolled in Cohorts 1 and 2, respectively. The combination of ipatasertib, atezolizumab and paclitaxel will be evaluated in Cohorts 1 and 2 and the combination of ipatasertib and paclitaxel will be evaluated in Cohort 1.

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society